Faster access to new drugs: Fault lines between Health Canada's regulatory intent and Industry innovation practices


Abstract This article has no associated abstract. (fix it)
Keywords No keywords specified (fix it)
Categories (categorize this paper)
DOI 10.1615/EthicsBiologyEngMed.2014010771
Options
Edit this record
Mark as duplicate
Export citation
Find it on Scholar
Request removal from index
Revision history

Download options

Our Archive


Upload a copy of this paper     Check publisher's policy     Papers currently archived: 45,629
External links

Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
Through your library

References found in this work BETA

No references found.

Add more references

Citations of this work BETA

No citations found.

Add more citations

Similar books and articles

Industry, Innovation and Social Values.Dr Harvey E. Bale Jr - 2005 - Science and Engineering Ethics 11 (1):31-40.
Industry, Innovation and Social Values.Harvey E. Bale - 2005 - Science and Engineering Ethics 11 (1):31-40.
Improving Abortion Access in Canada.Chris Kaposy - 2010 - Health Care Analysis 18 (1):17-34.
Corporate Responsibilities for Access to Medicines.Klaus M. Leisinger - 2009 - Journal of Business Ethics 85 (S1):3 - 23.

Analytics

Added to PP index
2014-06-06

Total views
12 ( #681,825 of 2,280,716 )

Recent downloads (6 months)
1 ( #837,375 of 2,280,716 )

How can I increase my downloads?

Downloads

My notes

Sign in to use this feature